<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yoshihara E</submitter><funding>NIDDK NIH HHS</funding><funding>NIEHS NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>622-34</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4832237</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(4)</volume><pubmed_abstract>Pancreatic β cells undergo postnatal maturation to achieve maximal glucose-responsive insulin secretion, an energy intensive process. We identify estrogen-related receptor γ (ERRγ) expression as a hallmark of adult, but not neonatal β cells. Postnatal induction of ERRγ drives a transcriptional network activating mitochondrial oxidative phosphorylation, the electron transport chain, and ATP production needed to drive glucose-responsive insulin secretion. Mice deficient in β cell-specific ERRγ expression are glucose intolerant and fail to secrete insulin in response to a glucose challenge. Notably, forced expression of ERRγ in iPSC-derived β-like cells enables glucose-responsive secretion of human insulin in vitro, obviating in vivo maturation to achieve functionality. Moreover, these cells rapidly rescue diabetes when transplanted into β cell-deficient mice. These results identify a key role for ERRγ in β cell metabolic maturation, and offer a reproducible, quantifiable, and scalable approach for in vitro generation of functional human β cell therapeutics.</pubmed_abstract><journal>Cell metabolism</journal><pubmed_title>ERRγ Is Required for the Metabolic Maturation of Therapeutically Functional Glucose-Responsive β Cells.</pubmed_title><pmcid>PMC4832237</pmcid><funding_grant_id>R01 HL105278</funding_grant_id><funding_grant_id>R37 DK057978</funding_grant_id><funding_grant_id>R01 DK057978</funding_grant_id><funding_grant_id>HL105278</funding_grant_id><funding_grant_id>P01 HL088093</funding_grant_id><funding_grant_id>P42 ES010337</funding_grant_id><funding_grant_id>DK090962</funding_grant_id><funding_grant_id>R24 DK090962</funding_grant_id><funding_grant_id>P30 CA014195</funding_grant_id><funding_grant_id>HL088093</funding_grant_id><funding_grant_id>P30 DK063491</funding_grant_id><funding_grant_id>ES010337</funding_grant_id><funding_grant_id>DK057978</funding_grant_id><pubmed_authors>Kida Y</pubmed_authors><pubmed_authors>Atkins AR</pubmed_authors><pubmed_authors>Wei Z</pubmed_authors><pubmed_authors>Dai Y</pubmed_authors><pubmed_authors>Yoshihara E</pubmed_authors><pubmed_authors>Downes M</pubmed_authors><pubmed_authors>Ahmadian M</pubmed_authors><pubmed_authors>Lin CS</pubmed_authors><pubmed_authors>Tseng T</pubmed_authors><pubmed_authors>Liddle C</pubmed_authors><pubmed_authors>Fang S</pubmed_authors><pubmed_authors>Yu RT</pubmed_authors><pubmed_authors>Evans RM</pubmed_authors></additional><is_claimable>false</is_claimable><name>ERRγ Is Required for the Metabolic Maturation of Therapeutically Functional Glucose-Responsive β Cells.</name><description>Pancreatic β cells undergo postnatal maturation to achieve maximal glucose-responsive insulin secretion, an energy intensive process. We identify estrogen-related receptor γ (ERRγ) expression as a hallmark of adult, but not neonatal β cells. Postnatal induction of ERRγ drives a transcriptional network activating mitochondrial oxidative phosphorylation, the electron transport chain, and ATP production needed to drive glucose-responsive insulin secretion. Mice deficient in β cell-specific ERRγ expression are glucose intolerant and fail to secrete insulin in response to a glucose challenge. Notably, forced expression of ERRγ in iPSC-derived β-like cells enables glucose-responsive secretion of human insulin in vitro, obviating in vivo maturation to achieve functionality. Moreover, these cells rapidly rescue diabetes when transplanted into β cell-deficient mice. These results identify a key role for ERRγ in β cell metabolic maturation, and offer a reproducible, quantifiable, and scalable approach for in vitro generation of functional human β cell therapeutics.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr</publication><modification>2026-04-12T23:54:39.601Z</modification><creation>2019-03-27T02:11:35Z</creation></dates><accession>S-EPMC4832237</accession><cross_references><pubmed>27076077</pubmed><doi>10.1016/j.cmet.2016.03.005</doi></cross_references></HashMap>